Page last updated: 2024-11-07

coclaurine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

coclaurine: RN given refers to (S)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(S)-coclaurine : The (S)-enantiomer of coclaurine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160487
CHEMBL ID446211
CHEBI ID15950
SCHEMBL ID20683184
MeSH IDM0045826

Synonyms (27)

Synonym
(1s)-1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
CHEBI:15950 ,
1-(p-hydroxybenzyl)-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinoline
(s)-coclaurine
486-39-5
C06161
coclaurine
machiline
(s)-1,2,3,4-tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-7-isoquinolinol
CHEMBL446211 ,
(1s)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
bdbm50292463
(-)-coclaurine
coclaurin
cw1576313y ,
unii-cw1576313y
1,2,3,4-tetrahydro-1-(p-hydroxybenzyl)-6-methoxy-7-isoquinolinol
coclaurine [mi]
(1s)-1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-6-methoxy-7-isoquinolinol
DTXSID60197561
AKOS032948470
FS-9925
CS-0023935
HY-N3610
SCHEMBL20683184
Q15633989
E80611
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coclaurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID359911Ratio of IC50 for rat striatum dopamine D2 receptor to IC50 for Wistar rat striatal synaptosomes dopamine transporter-mediated [3H]dopamine uptake1995Journal of natural products, Oct, Volume: 58, Issue:10
Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes.
AID359909Inhibition of dopamine transporter-mediated [3H]dopamine uptake in Wistar rat striatal synaptosomes by liquid scintillation spectrometry1995Journal of natural products, Oct, Volume: 58, Issue:10
Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes.
AID359910Ratio of IC50 for rat striatum dopamine D1 receptor to IC50 for Wistar rat striatal synaptosomes dopamine transporter-mediated [3H]dopamine uptake1995Journal of natural products, Oct, Volume: 58, Issue:10
Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's2 (11.76)18.2507
2000's3 (17.65)29.6817
2010's5 (29.41)24.3611
2020's3 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.74 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]